IU/mL.1 IU/mL A , % % 6.% 7 B %.1 IU/mL IU/mL % %.1 IU/mL % 7/9 4
|
|
|
- たつぞう きせんばる
- 7 years ago
- Views:
Transcription
1 7 1, KPA.1 IU/mL 21 9% %.1 IU/mL 1975 DPT % % Clostridium tetani DPT DPT 1981 DTaP212 DPT-IPV 7 7 1, KPA.2 IU/mL
2 IU/mL.1 IU/mL A , % % 6.% 7 B %.1 IU/mL IU/mL % %.1 IU/mL % 7/ % IU/mL 9% % 64.6% % DPT % % 12/16.1 IU/mL % 25/ % 41/ DPT % 6 C D
3 E % 98.% 99.3% 1% % 44.7% URL:
4 1 The number of examinees for tetanus susceptibility investigation by age group in each prefecture 213 Prefecture Age group years Hokkaido Tokyo Fukui Aichi Ehime Kochi Fukuoka
5 2 Age group distribution of tetanus antitoxin titer by prefecture 213 Prefecture Age group years Antitoxin titer IU/ml / / / / / / / G.M.T. Hokkaido Tokyo Fukui Aichi Ehime
6 2 Age group distribution of tetanus antitoxin titer by prefecture 213 Prefecture Age group years Antitoxin titer IU/ml / / / / / / / G.M.T. Kochi Fukuoka
7 3 Age distribution of tetanus antitoxin titer 213 Age years Antitoxin titer IU/ml / / / / / / / G.M.T
8 4 Age group distribution of tetanus antitoxin titer 213 Age group years Antitoxin titer IU/ml / / / / / / / G.M.T Age months 5 Age distribution of tetanus antitoxin titer in infants Antitoxin titer IU/ml / / / / / / / G.M.T
9 6 The number of examinees for tetanus susceptibility investigation by vaccination history and age group 213 Age group years Vaccination history Vaccinee 1 1 dose 2 2 doses 3 3 doses 4 4 doses 5 5 doses Others A B C D E F G H Nonvaccinee Unknown Vaccinee % Vaccinee % = B+C+D+E+F+G / A+B+C+D+E+F+G 1 Primary vaccination series : 4 doses DPT or DPT-IPV / Booster vaccination : 1 dose DT DPT : diphtheria-pertussis-tetanus combined vaccine / DPT-IPV : DPT-inactivated poliovirus combined vaccine DT : diphtheria-tetanus combined toxoid Prefecture Hokkaido Tokyo Fukui Aichi Ehime Kochi Fukuoka 7 The number of examinees for tetanus susceptibility investigation by vaccination history and prefecture Vaccination history Vaccinee Vaccinee Nonvaccinee Unknown % 1 dose 2 doses 3 doses 4 doses 5 doses Others A B C D E F G H Vaccinee % = B+C+D+E+F+G / A+B+C+D+E+F+G 1 Primary vaccination series : 4 doses DPT or DPT-IPV / Booster vaccination : 1 dose DT DPT : diphtheria-pertussis-tetanus combined vaccine / DPT-IPV : DPT-inactivated poliovirus combined vaccine DT : diphtheria-tetanus combined toxoid
10 8 Age group distribution of tetanus antitoxin titer by vaccination history 213 Vaccination history Age group years Antitoxin titer IU/ml / / / / / / / Non-vaccinee G.M.T Vaccinee : 1 dose Vaccinee : 2 doses Vaccinee : 3 doses
11 8 Age group distribution of tetanus antitoxin titer by vaccination history 213 Vaccination history Age group years 4 Antitoxin titer IU/ml / / / / / / / Vaccinee : 4 doses Vaccinee : 5 doses Primary vaccination series : 4 doses DPT or DPT-IPV / Booster vaccination : 1 dose DT DPT : diphtheria-pertussis-tetanus combined vaccine / DPT-IPV : DPT-inactivated poliovirus combined vaccine DT : diphtheria-tetanus combined toxoid G.M.T
12 1 213 Age distribution of tetanus antitoxin positives, 213 Antitoxin positives % n = 1315 Antitoxin titer IU/ml Age years 2213 Age group distribution of tetanus antitoxin positives, 213 Antitoxin positives % n = 1315 Antitoxin titer IU/ml Age group years
13 3213 Age group distribution of tetanus antitoxin positives in infants, 213 Antitoxin positives % Antitoxin titer IU/ml n = n = n = n = 21 Age group months No. of sample
14 4-1 /.1 IU/ml Age/age group distribution of tetanus antitoxin positives (titer.1 IU/ml) in different years Antitoxin positives % Year No. of sample 1998 n = n = n = n = 1315 age group in 1998 : result of 15 years Age/age group years 4-2 /.1 IU/ml Age/age group distribution of tetanus antitoxin positives (titer.1 IU/ml) in different years Antitoxin positives % Year No. of sample 1998 n = n = n = n = 1315 age group in 1998 : result of 15 years Age/age group years
15 5 213 Age group distribution of tetanus antitoxin positives in each prefecture, 213 Hokkaido Tokyo Fukui Antitoxin positives % n = 139 n = 358 n = 138 Antitoxin titer IU/ml Aichi Ehime Kochi Antitoxin positives % n = 14 n = 188 n = Age group years Fukuoka n = Age group years Antitoxin positives % Age group years
16 6 ( 19 ) 213 Tetanus antitoxin positives by vaccination history with antitoxin titer (-19 years old), 213 Cumulative antitoxin positives % Antitoxin titer IU/ml Vaccination history No. of sample Vaccinee : 5 doses n=41 Vaccinee : 4 doses n=253 Vaccinee : 3 doses n=82 Vaccinee : 2 doses n=58 Vaccinee : 1 dose n=7 Non-vaccinee n=11 Primary vaccination : 4 doses Booster vaccination : 1 dose
VERO IU/mL.1 IU/mL A , % % 6.% 7 B %.1 IU/mL IU/mL %.1 IU/mL 1
7 1,348 213 VERO.1 IU/mL 1 82.8% 1 5 9%.1 IU/mL 1 6 9 58.7% 1 46.2% 12 15 8%.1 IU/mL 2 3-34 7% 36.9%1975 DPT 4 54 5% 55 1958 12.9%.1 IU/mL Corynebacterium diphtheriae 1999 1948 1958 DP 1964 DPT 1968 1975
スライド 1
資料 3 不活化ポリオワクチンの円滑な導入に関する検討会第 3 回会議 ポリオワクチン互換性についての諸外国におけるデータ 2012 年 4 月 23 日 ( 月 ) 中野貴司 ( 川崎医科大学小児科 ) ワクチンの互換性 Interchangeability of vaccines 同一疾患を予防するワクチン製剤の種類が増え また多価混合ワクチンが普及すると 対象者が過去に接種したものと同じ製剤が入手できなかったり
2 3
Sample 2 3 4 5 6 7 8 9 3 18 24 32 34 40 45 55 63 70 77 82 96 118 121 123 131 143 149 158 167 173 187 192 204 217 224 231 17 285 290 292 1 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38
Vaccines for Your Children - Japanese
子どもの for Your Children help prevent disease. Babies born in the United States may have their first vaccines right after birth. Future vaccines are given at well child check-ups with your child s doctor
第2回：データの加工・整理
2 2018 4 13 1 / 24 1. 2. Excel 3. Stata 4. Stata 5. Stata 2 / 24 1 cross section data e.g., 47 2009 time series data e.g., 1999 2014 5 panel data e.g., 47 1999 2014 5 3 / 24 micro data aggregate data 4
02田澤里喜様.indd
2011 pp. 19 35 3 3 11 3 3 3 3 3 3 3 4 4 3 4 3 4 4 2 5 1 4 11 3 3 3 3 4 3 3 3 2012 1 18 19 2011 1 2010 3 3 2 12 4 3 3 3 3 3 3 3 3 3 9 54 10 7 4 3 2 2 38 5 31 1 173 55 229 5 0.9 6 20 3 32 1 33 195 15 7 6
-51-
-50- -51- 11 3 28 8 1 24 7 2 36 10 1-52- -53- 1 2-54- 6 1 2 3 4 5 6 6 1 19 5 200 300ml 20 6 400ml -55- -56- 10-57- 4 2 20-58- 2,500-59- -60- -61- 2-62- 6 3-63- 9 68 1 6-64- 3-65- 4-66- 5 6-67- -68- 1 1
<4D F736F F F696E74202D208E9197BF DAC8D87838F834E CC8A4A94AD8FF38BB C982C282A282C4817C82502E707074>
ワクチン産業ビジョン作成から現在までの主な活動 平成 19 年 3 月 : ワクチン産業ビジョン策定 平成 19 年 3 月 : ワクチン産業ビジョン推進委員会の立ち上げ 個別ワクチンの開発にかかる現状及び諸課題の網羅的な検討を開始 平成 20 年 3 月 : ワクチン産業ビジョン推進委員会ワーキンググループ検討とりまとめ 個別ワクチンの開発にかかる諸課題を整理するとともに 一部のワクチンについてさらに詳細を検討する必要性等を指摘
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 http://www.moj.go.jp/press/090130-1.html 55 56 57
324.pdf
50 50 10 30 11 26 12 27 14 16 27 18 20 21 22 22 22 22 23 24 24 1 No.324 JA 2 85 69 20 12 81 18 12 22 93 10 31 3 50 50 30 30 50 22 27 27 10 16 14 52 10 62 15 64 25 24 50 4 25 23 27 5 10 11 25 6 11 49 10
臨床的安全性 の略号一覧 略号 ( 略称 ) 定義 省略されていない名称 AE Adverse Event( 有害事象 ) AIDS Acquired Immune Deficiency Syndrome( 後天性免疫不全症候群 ) AOM Acute Otitis Media( 急性
2.7.4. 臨床的安全性 Feb 24 2015 17:16:00 2.7.4 - p. 1 2.7.4. 臨床的安全性 の略号一覧 略号 ( 略称 ) 定義 省略されていない名称 AE Adverse Event( 有害事象 ) AIDS Acquired Immune Deficiency Syndrome( 後天性免疫不全症候群 ) AOM Acute Otitis Media( 急性中耳炎
1311
国内コンビニエンスストアコンビニエンスストアの店舗数店舗数の推移 推移 Number of stores in Japan *1 2012 年度 3Q/FY FY2012 2013 年度 3Q/FY FY2013 2013 年度計画 /FY FY2013 2013(Forecast Forecast) 2012.3.1-2012.11.30 2013.3.1-2013.11.30 2013.3.1-2014.2.28
ñ{ï 01-65
191252005.2 19 *1 *2 *3 19562000 45 10 10 Abstract A review of annual change in leading rice varieties for the 45 years between 1956 and 2000 in Japan yielded 10 leading varieties of non-glutinous lowland
10Disclosure_H0104_0618
01 SHIZUOKA BANK GROUP REPORT 2010 SHIZUOKA BANK GROUP REPORT 2010 02 03 SHIZUOKA BANK GROUP REPORT 2010 SHIZUOKA BANK GROUP REPORT 2010 04 05 SHIZUOKA BANK GROUP REPORT 2010 06 SHIZUOKA BANK GROUP REPORT
取扱説明書 [N-03A]
![取扱説明書 [N-03A]](/thumbs/39/20475381.jpg "取扱説明書 [N-03A]")
235 1 d dt 2 1 i 236 1 p 2 1 ty 237 o p 238 1 i 2 1 i 2 1 u 239 1 p o p b d 1 2 3 0 w 240 241 242 o d p f g p b t w 0 q f g h j d 1 2 d b 5 4 6 o p f g p 1 2 3 4 5 6 7 243 244 1 2 1 q p 245 p 246 p p 1
untitled
HBV HBV (1964) HDV (1977) HCV (1988) 2009 Yotsuyanagi H et al. J Med Virol 2005 Yotsuyanagi H et al. J Hepatol 2002 Universal vaccination (UV) 45 HB 2009 1/3 Progress Toward the Elimination
特集・総説・報告（４４行）／Ｐ０４５－０５５＿報告 日本肝移植研究会
45 Liver Transplantation in Japan in 2006 Part 2 Registry by the The Summary Four thousand three hundred thirty liver transplants have been performed as of December 31, 2006 in 59 institutions in Japan.
<82E682B15F8FBC88E48D828BB42E696E6464>
See Boundary space and human consciousness from holy place and monster s distribution MATSUI Koichi TAKAHASHI Seiichi Amami Oshima has created own unique culture, which is based on Ryukyu culture and also
【資料４】「同時接種・接種間隔について」（中野委員説明資料）
予防接種に関する基本的な計画 における PDCA サイクルにかかるヒアリング 資料 4 同時接種 接種間隔 について 中野貴司 ( 川崎医科大学小児科 ) 平成 29 年 4 月 27 日 ( 木 ) 第 18 回厚生科学審議会予防接種 ワクチン分科会予防接種基本方針部会 1 予防接種に関する基本的な計画 計画 予防接種に関する基本的な計画 ( 厚生労働省告示第百二十一号, 平成 26 年 4 月から適用
01p
M o n t h l y R i n r i A i c h i RINRI AICHI 10.2011 RINRI AICHI 10.2011 RINRI AICHI 10.2011 RINRI AICHI 10.2011 RINRI AICHI 10.2011 RINRI AICHI 10.2011 RINRI AICHI 10.2011 RINRI AICHI 10.2011 RINRI AICHI
01
M o n t h l y R i n r i A i c h i RINRI AICHI 9.2011 h RINRI AICHI 9.2011 RINRI AICHI 9.2011 RINRI AICHI 9.2011 RINRI AICHI 9.2011 RINRI AICHI 9.2011 RINRI AICHI 9.2011 k x RINRI AICHI 9.2011 RINRI AICHI
100sen_Eng_h1_4
Sapporo 1 Hakodate Japan 5 2 3 Kanazawa 15 7 Sendai Kyoto Kobe 17 16 10 9 18 20 Hiroshima 11 8 32 31 21 28 26 19 Fukuoka 33 25 13 35 34 23 22 14 12 40 37 27 24 29 41 38 Tokyo 36 42 44 39 30 Nagoya Shizuoka
52-2.indb
Jpn. J. Health Phys., 52 (2) 55 60 (2017) DOI: 10.5453/jhps.52.55 * 1 * 2 * 2 * 3 * 3 2016 10 28 2017 3 8 Enhancement of Knowledge on Radiation Risk Yukihiko KASAI,* 1 Hiromi KUDO,* 2 Masahiro HOSODA,*
Title 生活年令による学級の等質化に関する研究 (1) - 生活年令と学業成績について - Author(s) 与那嶺, 松助 ; 東江, 康治 Citation 研究集録 (5): 33-47 Issue Date 1961-12 URL http://hdl.handle.net/20.500.12000/ Rights 46 STUDIES ON HOMOGENEOUS